Alterity Therapeutics
ATHE
20 hedge funds and large institutions have $368K invested in Alterity Therapeutics in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
1,925% more call options, than puts
Call options by funds: $81K | Put options by funds: $4K
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
5% less funds holding
Funds holding: 21 → 20 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
33% less capital invested
Capital invested by funds: $553K → $368K (-$185K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$58.1K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$23.6K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$13.3K |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$11.1K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$123K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$21.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$21K |
| 4 |
CAM
Columbia Asset Management
Ann Arbor,
Michigan
|
-$5.33K |
| 5 |
Morgan Stanley
New York
|
-$4.75K |
ATHE Hedge Fund Activity: Q3 2015 in Review
20 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q3 2015, worth a combined $368K — down 33% from $553K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ATHE and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, adding an estimated $58.1K. The largest seller was Virtu KCG Holdings, cutting an estimated $123K.
- 20 institutional investors held Alterity Therapeutics (ATHE) as of Q3 2015, down from 21 in Q2 2015.
- Funds reported $368K of Alterity Therapeutics stock for Q3 2015, down 33% quarter-over-quarter.
- 3 funds opened new Alterity Therapeutics positions in Q3 2015 and 4 closed out, a net change of -1 holder.
- The largest Alterity Therapeutics buyer in Q3 2015 was Citadel Advisors, an estimated $58.1K added.
- The largest Alterity Therapeutics seller in Q3 2015 was Virtu KCG Holdings, an estimated $123K sold.
Based on aggregated 13F filings for Q3 2015.